In the intricate world of pharmaceutical manufacturing, the quality and availability of chemical intermediates are fundamental to the success of drug production. One such vital compound is 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline (CAS: 183377-18-1), a crucial intermediate in the synthesis of Erlotinib. This article aims to provide a comprehensive overview of this compound, detailing its chemical properties, its indispensable role in creating Erlotinib, and why its sourcing is a critical consideration for R&D scientists and procurement managers.

4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline is characterized by its chemical name and a specific molecular formula (C14H17ClN2O4) and molecular weight (312.75). Physically, it typically presents as a white to off-white crystalline powder. Its specifications are meticulously defined, with a high purity standard of ≥99% and strict controls on water content (≤0.5%), residue on ignition (≤0.1%), and total and single impurities (≤0.5% and ≤0.1% respectively). These stringent quality parameters are essential as this intermediate directly influences the final API’s efficacy and safety profile.

The primary and most significant application of 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline is its function as an intermediate in the synthesis of Erlotinib. Erlotinib is a targeted therapy drug used primarily for treating non-small cell lung cancer and pancreatic cancer by inhibiting the epidermal growth factor receptor (EGFR). The chemical structure of this quinazoline derivative makes it perfectly suited for the specific reaction pathways required to build the complex molecular framework of Erlotinib. Therefore, securing a reliable supply of high-quality 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline is a non-negotiable aspect for any pharmaceutical manufacturer involved in Erlotinib production.

For research scientists and product formulators, understanding the properties and applications of such intermediates is key to optimizing synthetic routes and ensuring product integrity. Companies that manufacture or supply this compound play a critical role in the pharmaceutical supply chain. When considering a purchase, it is advisable to buy from manufacturers that can provide detailed analytical data, batch consistency, and robust customer support. This ensures that your research and manufacturing processes are supported by dependable raw materials. Inquiring about the price and availability for bulk orders from established suppliers is a standard practice for efficient procurement.

The journey from intermediate to finished API is complex, and the choice of intermediate supplier is a strategic decision. Opting for a manufacturer with a proven track record in producing high-purity pharmaceutical intermediates like 4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline from China can offer significant advantages in terms of cost, scale, and technical expertise. This allows businesses to focus on their core competencies, such as drug development and market delivery, with confidence in their raw material sourcing.